Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
Analysts anticipate Twist Bioscience to report an earnings per share (EPS) of $-0.46. Anticipation surrounds Twist Bioscience ...
The price of gold has rebounded over the past week after slumping for a few weeks following a series of record highs. Several ...
Barchart on MSN
Should You Buy the Dip in Intellia Therapeutics Stock?
In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.
AppLovin Reports Strong Earnings. The Stock Is Up. Revenue for AppLovin’s mobile advertising business was up 68% on the year to $1.41 billion. The Snapchat parent reported third-quarter earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback